Source:Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis.
J Pediatr.
2001
;
139
:
380
–384.

A cluster of cases suggested that infants treated with oral erythromycin may have an increased risk of developing infantile hypertrophic pyloric stenosis (IHPS).1 Investigators at Indiana University performed a retrospective cohort study to re-examine the risk of IHPS among infants receiving systemic treatment with a macrolide antibiotic, infants prescribed a therapeutic course of ophthalmic erythromycin ointment, and infants whose mothers received macrolide antibiotics during pregnancy. The study included all infants born at an urban hospital between June 1, 1993, and December 31, 1999, who were seen within the first 3 months of life at the hospital’s affiliated network of clinics and who survived for at least 3 months. Exposure to macrolides was determined from prescriptions using...

You do not currently have access to this content.